{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:16:16Z","timestamp":1794255376773,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11090-3","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:08:58Z","timestamp":1748344138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study"],"prefix":"10.1186","volume":"25","author":[{"given":"Nicola","family":"Squillace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Delfina","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Forcina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Piconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Francesco","family":"Pellican\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto Maurizio","family":"Celesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Salomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"11090_CR1","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.24875\/AIDSRev.19000023","volume":"21","author":"C Hoffmann","year":"2019","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDSRev. 2019;21:1768.","journal-title":"AIDSRev"},{"key":"11090_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/COH.0000000000000705","volume":"16","author":"T Senneker","year":"2021","unstructured":"Senneker T, Tseng A. An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors. Curr Opin HIV AIDS. 2021;16:309\u201320.","journal-title":"Curr Opin HIV AIDS"},{"key":"11090_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","volume":"21","author":"I P\u00e9rez-Valero","year":"2023","unstructured":"P\u00e9rez-Valero I, Corona D, Mart\u00ednez N, L\u00f3pez-Cavanillas M, Lluis C, Luque I. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review. Expert Rev Anti-infective Therapy. 2023;21:655\u201365.","journal-title":"Expert Rev Anti-infective Therapy"},{"key":"11090_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/jac\/dkae011","volume":"79","author":"J Troya","year":"2024","unstructured":"Troya J, Pousada G, Mic\u00e1n R, Galera C, Sanz J, De Los Santos I, et al. Real-life data of immune recovery using bictegravir\/emtricitabine\/tenofovir Alafenamide in virologically suppressed people living with HIV. Results at 48\u201396 weeks of RETROBIC study. J Antimicrob Chemother. 2024;79:595\u2013607.","journal-title":"J Antimicrob Chemother"},{"key":"11090_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, Levy I, D\u2019Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir Alafenamide in people with HIV: Real\u2010world insights from bicstar cohorts. HIV Med. 2024;25:440\u201353.","journal-title":"HIV Med"},{"key":"11090_CR6","doi-asserted-by":"publisher","first-page":"107164","DOI":"10.1016\/j.ijantimicag.2024.107164","volume":"63","author":"C Hidalgo-Tenorio","year":"2024","unstructured":"Hidalgo-Tenorio C, Sequera S, Vivancos MJ, Vinuesa D, Collado A, Santos IDL, et al. Bictegravir\/emtricitabine\/tenofovir Alafenamide as first-line treatment in Na\u00efve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial. Int J Antimicrob Agents. 2024;63:107164.","journal-title":"Int J Antimicrob Agents"},{"key":"11090_CR7","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.2105\/AJPH.2018.304843","volume":"109","author":"N Jeffries","year":"2019","unstructured":"Jeffries N, Zaslavsky AM, Diez Roux AV, Creswell JW, Palmer RC, Gregorich SE, et al. Methodological approaches to Understanding causes of health disparities. Am J Public Health. 2019;109:S28\u201333.","journal-title":"Am J Public Health"},{"key":"11090_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.18773\/austprescr.2018.017","volume":"41","author":"JF Gilmartin-Thomas","year":"2018","unstructured":"Gilmartin-Thomas JF, Liew D, Hopper I. Observational studies and their utility for practice. Aust Prescr. 2018;41:82\u20135.","journal-title":"Aust Prescr"},{"key":"11090_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.qai.0000164248.56722.3c","volume":"39","author":"P Bonfanti","year":"2005","unstructured":"Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance cohort Long-Term toxicity Antiretrovirals) project on the safety of Lopinavir\/Ritonavir. JAIDS J Acquir Immune Defic Syndr. 2005;39:317\u201320.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"11090_CR10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"11090_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"11090_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/dar.13681","volume":"42","author":"T Norman","year":"2023","unstructured":"Norman T, Power J, Clifton B, Murray J, Bourne A. People living with HIV who inject or have injected non-prescription drugs: evidence of substantial differences in health inequalities and experiences of clinical care. Drug Alcohol Rev. 2023;42:1517\u201328.","journal-title":"Drug Alcohol Rev"},{"key":"11090_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drugpo.2019.03.002","volume":"71","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Bharat C, Glantz MD, Sampson NA, Scott K, Lim CCW, et al. The epidemiology of drug use disorders cross-nationally: findings from the who\u2019s world mental health surveys. Int J Drug Policy. 2019;71:103\u201312.","journal-title":"Int J Drug Policy"},{"key":"11090_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/QAD.0000000000001708","volume":"32","author":"EF Eaton","year":"2018","unstructured":"Eaton EF, Tamhane A, Davy-Mendez T, Mathews WC, Moore RD, Saag MS, et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS. 2018;32:347\u201355.","journal-title":"AIDS"},{"key":"11090_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1468-1293.2009.00779.x","volume":"11","author":"D Moore","year":"2010","unstructured":"Moore D, Zhang W, Yip B, Genebat M, Lima V, Montaner J, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11:299\u2013307.","journal-title":"HIV Med"},{"key":"11090_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1468-1293.2009.00750.x","volume":"11","author":"P Cicconi","year":"2010","unstructured":"Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi E, Antinori A, Gatti F, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral\u2010na\u00efve patients. HIV Med. 2010;11:104\u201313.","journal-title":"HIV Med"},{"key":"11090_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1089\/aid.2024.0002","volume":"40","author":"ME Byrne","year":"2024","unstructured":"Byrne ME, Resnik JB, Horberg MA, Greenberg AE, Castel AD, Monroe AK. Factors associated with time to initial antiretroviral therapy discontinuation in the DC cohort. AIDS Res Hum Retroviruses. 2024;40:671\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"11090_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10461-020-02967-2","volume":"25","author":"AR Kamkwalala","year":"2021","unstructured":"Kamkwalala AR, Wang K, O\u2019Halloran J, Williams DW, Dastgheyb R, Fitzgerald KC, et al. Starting or switching to an integrase Inhibitor-Based regimen affects PTSD symptoms in women with HIV. AIDS Behav. 2021;25:225\u201336.","journal-title":"AIDS Behav"},{"key":"11090_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40263-013-0132-4","volume":"28","author":"MS Abers","year":"2014","unstructured":"Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014;28:131\u201345.","journal-title":"CNS Drugs"},{"key":"11090_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s13365-012-0120-3","volume":"18","author":"K Robertson","year":"2012","unstructured":"Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18:388\u201399.","journal-title":"J Neurovirol"},{"key":"11090_CR21","doi-asserted-by":"publisher","first-page":"1118580","DOI":"10.3389\/fphar.2023.1118580","volume":"14","author":"C Huang","year":"2023","unstructured":"Huang C, Hoque T, Bendayan R. Antiretroviral drugs Efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function. Front Pharmacol. 2023;14:1118580.","journal-title":"Front Pharmacol"},{"key":"11090_CR22","doi-asserted-by":"publisher","first-page":"e23790","DOI":"10.1096\/fj.202400558R","volume":"38","author":"C Huang","year":"2024","unstructured":"Huang C, Hoque MT, Qu QR, Henderson J, Bendayan R. Antiretroviral drug dolutegravir induces inflammation at the mouse brain barriers. FASEB J. 2024;38:e23790.","journal-title":"FASEB J"},{"key":"11090_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/jac\/dky508","volume":"74","author":"A Borghetti","year":"2019","unstructured":"Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D\u2019Avolio A, et al. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019;74:1035\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"11090_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3851\/IMP3119","volume":"22","author":"D Cattaneo","year":"2017","unstructured":"Cattaneo D, Minisci D, Cozzi V, Riva A, Meraviglia P, Clementi E, et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?? Antivir Ther. 2017;22:353\u20136.","journal-title":"Antivir Ther"},{"key":"11090_CR25","doi-asserted-by":"publisher","first-page":"ofaa482","DOI":"10.1093\/ofid\/ofaa482","volume":"7","author":"I Perez Valero","year":"2020","unstructured":"Perez Valero I, Cabello A, Ryan P, De La Fuente-Moral S, Santos I, Vivancos MJ, et al. Randomized trial evaluating the neurotoxicity of dolutegravir\/abacavir\/lamivudine and its reversibility after switching to Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide: GESIDA 9016. Open Forum Infect Dis. 2020;7:ofaa482.","journal-title":"Open Forum Infect Dis"},{"key":"11090_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAD.0000000000001351","volume":"31","author":"P Bonfanti","year":"2017","unstructured":"Bonfanti P, Madeddu G, Gulminetti R, Squillace N, Orofino G, Vitiello P, et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017;31:455\u20137.","journal-title":"AIDS"},{"key":"11090_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/QAD.0000000000001357","volume":"31","author":"A Borghetti","year":"2017","unstructured":"Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, et al. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017;31:457\u20139.","journal-title":"AIDS"},{"key":"11090_CR28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","volume":"31","author":"L Elzi","year":"2017","unstructured":"Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31:1853\u20138.","journal-title":"AIDS"},{"key":"11090_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink H, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56\u201363.","journal-title":"HIV Med"},{"key":"11090_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/jac\/dkad026","volume":"78","author":"A D\u2019arminio Monforte","year":"2023","unstructured":"D\u2019arminio Monforte A, Tavelli A, Sala M, Mondi A, Rusconi S, Antinori S, et al. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. J Antimicrob Chemother. 2023;78:933\u201345.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11090-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:08:59Z","timestamp":1748344139000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11090-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11090"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11090-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SCOLTA Project was conducted in accordance with the Declaration of Helsinki. The ethical approval was originally obtained by the Ethics Committee of the L.Sacco Hospital, where the principal investigator (dr. Rizzardini) was working at the time. Amendments were requested in 2013, 2019, 2020 and 2023: with this last amendment, the role of Principal Investigator was taken by dr. Bonfanti (IRCCS San Gerardo Monza), and the reference Ethics Committee changed. The original study protocol was approved on 18 September 2002, and three amendments were approved on 13 June 2013, 20 December 2019, 12 May 2020 and 12 June 2023 by the coordinating center at Hospital \u201cL. Sacco\u201d-University of Milan, Milan (Italy), and thereafter by all participating centers. Written consent for study participation was obtained from all participants, and the study was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and by Italian national laws. All patients starting one of the drugs included in the surveillance program in participating centers are consecutively asked to participate in the study after signing a written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N.S. received grants for educational activity, speaker\u2019s fee, advisory board, research projects and for conferences\u2019attending by Gilead Sciences and speaker\u2019s fee and grant for attending conferences by ViiV Healthcare. P.M. received: Grant for publication, Advisory board fees, Conference hospitality: Gilead Science; Advisory board fees: ViiV Healthcare; Advisory board fees, Conference hospitality: MSD, Advisory board fees, Conference hospitality: Janssen. P.B. received advisory board fees by Viiv, Gilead, MSD and AstrazenecaB.M.C. reported honoraria for presentations and scientific advice from Gilead Sciences, ViiV Healthcare, Janssen\u2010Cilag, Mylan, GSK vaccines and Merck Sharp & Dohme and researchgrants for his institution from Gilead Sciences, ViiV Healthcare GSK vaccines and Merck Sharp &and Dohme. G.V.D.S. received speaker\u2019s fees from Gilead Sciences and ViiV HealthcareF. Lparticipated on advisory boards sponsored by ViiV Healthcare, Janssen and recevide research grant from Gilead A.D.B. has received speakers\u2019 honoraria from Gilead, ViiV and Janssen-Cilag, has been an advisor for ViiV, Gilead and MSD, and has received grant for research from Gilead Sciences and ViiV healthcare.All the other authors declared no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"763"}}